Peripheral Neuropathy Clinical Trial
Official title:
Electrophysiological Evaluation of Motor Dysfunction in Liver Cirrhotic Patients
Verified date | April 2020 |
Source | Kasr El Aini Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
cross sectional observational study, aimed to assess the electrophysiological function of the motor units in liver cirrhotic patients.
Status | Completed |
Enrollment | 56 |
Est. completion date | March 5, 2020 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Both genders. - Age interval range between 18 and 60 years (To avoid maturational changes and aging process on motor unit number). - Liver cirrhotic patients( including compensated and decompensated patients); - Presenting hematemesis/melena and/or ascites. - Diagnosis of liver cirrhosis is confirmed by abdominal ultrasound Exclusion Criteria: - Patients with identifiable cause of peripheral neuropathy (e.g. diabetic patients) . - Patients who developed hepatocellular carcinoma (to avoid para-neoplastic syndrome e.g. peripheral neuropathy) - Patients with other non-hepatic chronic illness such as: patients with renal disease (to avoid other causes of metabolic neuropathies). |
Country | Name | City | State |
---|---|---|---|
Egypt | Kasr Alainy Teaching Hospital-Clinical Neurophysiology Unit | Giza |
Lead Sponsor | Collaborator |
---|---|
Kasr El Aini Hospital |
Egypt,
• Abdel-Razek, W., Hassany, M., Kabil, K., Ammar, I., Dabous, H., Doss, W., ... & El-Serafy, M. (2019). The World's Largest Hepatitis C Screening Program in Egypt. Journal of Hepatology (Vol. 70, pp. 144-145). • Abrams, G. A., Concato, J., & Fallon, M. B. (1996). Muscle cramps in patients with cirrhosis. American Journal of Gastroenterology, 91(7). • Aggarwal A, Nicholson G. (2002).Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. Journal of Neurology, Neurosurgery & Psychiatry; 73(2):199-201. • Amodio, P., & Gatta, A. (2005). Neurophysiological investigation of hepatic encephalopathy. Metabolic brain disease, 20(4), 369-379. • Arabadzhiev, T. I., Dimitrov, G. V., Dimitrov, A. G., Chakarov, V. E., & Dimitrova, N. A. (2008). Factors affecting the turns analysis of the interference EMG signal. Biomedical Signal Processing and Control, 3(2), 145-153. • Barkhaus, P. E. (2001). Motor Unit Action Potential Quantitation. In An AAEM workshop. Rochester, Minn: American Association of Electrodiagnostic Medicine (Vol. 2). • Bessou, P., Emonet-Dénand, F., & Laporte, Y. (1965). Motor fibres innervating extrafusal and intrafusal muscle fibres in the cat. The Journal of Physiology, 180(3), 649-672. • Blok, J. H., van Dijk, J. P., Drost, G., Zwarts, M. J., & Stegeman, D. F. (2002). A high-density multichannel surface electromyography system for the characterization of single motor units. Review of Scientific Instruments, 73(4), 1887-1897.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Early detection of peripheral neuropathy among liver cirrhotic patients. | Using nerve conduction studies of the: left ulnar,left posterior tibial and right deep peroneal motor nerves;assess their distal latency (measured in milliseconds) ,amplitude (measured in millivolts) and conduction velocities (measured in m/s).In addition , to sensory studies of the left ulnar and right sural sensory nerves; assessment of peak latency (measured in milliseconds) , amplitude (measured in microvolts) and their conduction velocities(measured in m/s) . Compare the values with our normative values. Detect evidence of peripheral neuropathy ( increased in distal latency above the upper limit of its normal value, decreased conduction velocity below the lower limit of its normal value and decreased amplitude below lower limit of its normal value). A minimum of three variables in two or more nerves are required to diagnose polyneuropathy as referenced by (Meulstee & Van Der Meche , 1995). |
baseline | |
Secondary | Detection of correlation between neuropathy and severity of liver cirrhosis. | Finding out any correlation between peripheral neuropathy and severity of liver cirrhosis: Comparing between patients with evidence of peripheral neuropathy (as detected by nerve conduction studies) and those without evidence of peripheral neuropathy versus the severity of their liver disease ( as assessed by Child-Pugh class) using Mann Whitney U test; to find out if their is statistical difference between them or not; denoting the presence/absence of correlation between peripheral neuropathy and the severity of the liver disease. |
baseline | |
Secondary | Motor unit number estimation using Spike-Triggered method. | Estimation of motor unit number using Spike-Triggered method in liver cirrhotic patients and age/gender healthy controls to find out of there is statistical difference between them. Decline in MUNE values denotes loss of motor neurons. |
Baseline | |
Secondary | Correlation of MUNE values to fatigue | Comparing between liver cirrhotic patients who reported fatigue(as part of their neurological symptoms) versus those who didn't report fatigue, regarding their MUNE values; using Mann Whitney U test. If there is statistical difference between them; there would be correlation between loss of motor units and fatigue reported by the patients(this assumption was based on (Heckman & Enoka, 2012) &(Mota et al., 2020) conclusions that there is positive correlation between fatigability and loss of motor units. |
Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05152368 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy
|
Phase 1 | |
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Completed |
NCT02549534 -
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02701075 -
MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain
|
N/A | |
Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
Completed |
NCT00763087 -
Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet
|
N/A | |
Completed |
NCT00079807 -
Painful HIV Neuropathy and Alpha-Lipoic Acid
|
Phase 1/Phase 2 | |
Completed |
NCT03292328 -
Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05379140 -
Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV
|
N/A | |
Recruiting |
NCT05673746 -
Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
|
N/A | |
Completed |
NCT05189535 -
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
|
Phase 2/Phase 3 | |
Recruiting |
NCT06219590 -
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
|
N/A | |
Enrolling by invitation |
NCT05595109 -
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05916118 -
Exercise and Oxaliplatin-induced Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT03881748 -
Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT02936843 -
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
|
Phase 2/Phase 3 | |
Terminated |
NCT01458015 -
Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01006408 -
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 |